論文・総説 - 中島　友紀

分割表示 >> ／  全件表示  189 件中 1 - 189 件目

  1. Yifan Qing, Takehito Ono, Yukihiro Kohara, Atsushi Watanabe, Noboru Ogiso, Masako Ito, Tomoki Nakashima, Sunao Takeshita. Emilin2 marks the target region for mesenchymal cell accumulation in bone regeneration. Inflamm Regen. 2024.06; 44 (1): 27. ( PubMed, DOI )

  2. Takuya Ogawa, Jingyi Xue, Long Guo, Maristela Sayuri Inoue-Arai, Siulan Vendramini-Pittoli, Roseli Maria Zechi-Ceide, Rosana Maria Candido-Souza, Cristiano Tonello, Michele Madeira Brandão, Terumi Okada Ozawa, Adriano Porto Peixoto, Daniela Maria Cury Ferreira Ruiz, Tomoki Nakashima, Shiro Ikegawa, Keiji Moriyama, Nancy Mizue Kokitsu-Nakata. Identification of a de novo PUF60 variant associated with craniofacial microsomia. Am J Med Genet A. 2024.04; e63631. ( PubMed, DOI )

  3. Anhao Liu, Mikihito Hayashi, Yujin Ohsugi, Sayaka Katagiri, Shizuo Akira, Takanori Iwata, Tomoki Nakashima. The IL-33/ST2 axis is protective against acute inflammation during the course of periodontitis. Nat Commun. 2024.03; 15 (1): 2707. ( PubMed, DOI )

  4. Naomi Toyama, Takehito Ono, Takashi Ono, Tomoki Nakashima. The interleukin-6 signal regulates orthodontic tooth movement and pain. Biochem Biophys Res Commun. 2023.12; 684 149068. ( PubMed, DOI )

  5. Bingzi Dong, Masahiro Hiasa, Yoshiki Higa, Yukiyo Ohnishi, Itsuro Endo, Takeshi Kondo, Yuichi Takashi, Maria Tsoumpra, Risa Kainuma, Shun Sawatsubashi, Hiroshi Kiyonari, Go Shioi, Hiroshi Sakaue, Tomoki Nakashima, Shigeaki Kato, Masahiro Abe, Seiji Fukumoto, Toshio Matsumoto. Osteoblast/osteocyte-derived interleukin-11 regulates osteogenesis and systemic adipogenesis. Nat Commun. 2022.11; 13 (1): 7194. ( PubMed, DOI )

  6. Yu Yamashita, Mikihito Hayashi, Mitsuru Saito, Tomoki Nakashima. Osteoblast lineage cells-derived Sema3A regulates bone homeostasis independently of androgens. Endocrinology. 2022.08; ( PubMed, DOI )

  7. Takehito Ono, Ryosuke Denda, Yuta Tsukahara, Takashi Nakamura, Kazuo Okamoto, Hiroshi Takayanagi, Tomoki Nakashima. Simultaneous augmentation of muscle and bone by locomomimetism through calcium-PGC-1α signaling. Bone Res. 2022.08; 10 (1): 52. ( PubMed, DOI )

  8. Masayuki Tsukasaki, Noriko Komatsu, Takako Negishi-Koga, Nam Cong-Nhat Huynh, Ryunosuke Muro, Yutaro Ando, Yuka Seki, Asuka Terashima, Warunee Pluemsakunthai, Takeshi Nitta, Takashi Nakamura, Tomoki Nakashima, Shinsuke Ohba, Haruhiko Akiyama, Kazuo Okamoto, Roland Baron, Hiroshi Takayanagi. Periosteal stem cells control growth plate stem cells during postnatal skeletal growth. Nat Commun. 2022.07; 13 (1): 4166. ( PubMed, DOI )

  9. Takehito Ono, Tomoki Nakashima. Oral bone biology. J Oral Biosci. 2022.03; 64 (1): 8-17. ( PubMed, DOI )

  10. Lin Liu, Hiroyuki Koike, Takehito Ono, Shinichiro Hayashi, Fujimi Kudo, Atsushi Kaneda, Hiroyuki Kagechika, Ichiro Manabe, Tomoki Nakashima, Yumiko Oishi. Identification of a KLF5-dependent program and drug development for skeletal muscle atrophy. Proc Natl Acad Sci U S A. 2021.08; 118 (35): ( PubMed, DOI )

  11. Long Guo, Aritoshi Iida, Gandham SriLakshmi Bhavani, Kalpana Gowrishankar, Zheng Wang, Jing-Yi Xue, Juan Wang, Noriko Miyake, Naomichi Matsumoto, Takanori Hasegawa, Yusuke Iizuka, Masashi Matsuda, Tomoki Nakashima, Masaki Takechi, Sachiko Iseki, Shinsei Yambe, Gen Nishimura, Haruhiko Koseki, Chisa Shukunami, Katta M Girisha, Shiro Ikegawa. Deficiency of TMEM53 causes a previously unknown sclerosing bone disorder by dysregulation of BMP-SMAD signaling. Nat Commun. 2021.04; 12 (1): 2046. ( PubMed, DOI )

  12. Noriko Komatsu, Stephanie Win, Minglu Yan, Nam Cong-Nhat Huynh, Shinichiro Sawa, Masayuki Tsukasaki, Asuka Terashima, Warunee Pluemsakunthai, George Kollias, Tomoki Nakashima, Hiroshi Takayanagi. Plasma cells promote osteoclastogenesis and periarticular bone loss in autoimmune arthritis. J Clin Invest. 2021.03; 131 (6): ( PubMed, DOI )

  13. Fumiyuki Sasaki, Mikihito Hayashi, Takehito Ono, Tomoki Nakashima. The regulation of RANKL by mechanical force. J Bone Miner Metab. 2021.01; 39 (1): 34-44. ( PubMed, DOI )

  14. Nasir K Bashiruddin, Mikihito Hayashi, Masanobu Nagano, Yan Wu, Yukiko Matsunaga, Junichi Takagi, Tomoki Nakashima, Hiroaki Suga. Development of cyclic peptides with potent in vivo osteogenic activity through RaPID-based affinity maturation. Proc Natl Acad Sci U S A. 2020.12; 117 (49): 31070-31077. ( PubMed, DOI )

  15. Hayashi M, Ono T, Nakashima T.. Signaling in osteoblast differentiation. Encyclopedia of Bone Biology. 2020.07; 416-426.

  16. Yosuke Tsuchiya, Mikihito Hayashi, Katashi Nagamatsu, Takehito Ono, Masaki Kamakura, Takanori Iwata, Tomoki Nakashima. The key royal jelly component 10-hydroxy-2-decenoic acid protects against bone loss by inhibiting NF-κB signaling downstream of FFAR4. J. Biol. Chem.. 2020.07; ( PubMed, DOI )

  17. Y Kameo, Y Miya, M Hayashi, T Nakashima, T Adachi. In silico experiments of bone remodeling explore metabolic diseases and their drug treatment. Sci Adv. 2020.03; 6 (10): eaax0938. ( PubMed, DOI )

  18. Takehito Ono, Mikihito Hayashi, Fumiyuki Sasaki, Tomoki Nakashima. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020.02; 40 2. ( PubMed, DOI )

  19. Yusoon Kim, Mikihito Hayashi, Takehito Ono, Tetsuya Yoda, Hiroshi Takayanagi, Tomoki Nakashima. Suppression of hematopoietic cell kinase ameliorates the bone destruction associated with inflammation. Mod Rheumatol. 2020.01; 30 (1): 85-92. ( PubMed, DOI )

  20. Fumiyuki Sasaki, Mikihito Hayashi, Yuki Mouri, Satoshi Nakamura, Taiji Adachi, Tomoki Nakashima. Mechanotransduction via the Piezo1-Akt pathway underlies Sost suppression in osteocytes. Biochem Biophys Res Commun. 2020.01; 521 (3): 806-813. ( PubMed, DOI )

  21. Jing-Yi Xue, Zheng Wang, Satoshi Shinagawa, Hirofumi Ohashi, Nao Otomo, Nursel H Elcioglu, Tomoki Nakashima, Gen Nishimura, Shiro Ikegawa, Long Guo. TNFRSF11A-Associated Dysosteosclerosis: A Report of the Second Case and Characterization of the Phenotypic Spectrum. J. Bone Miner. Res.. 2019.10; 34 (10): 1873-1879. ( PubMed, DOI )

  22. Mikihito Hayashi, Tomoki Nakashima, Noriko Yoshimura, Kazuo Okamoto, Sakae Tanaka, Hiroshi Takayanagi. Autoregulation of Osteocyte Sema3A Orchestrates Estrogen Action and Counteracts Bone Aging. Cell Metab.. 2019.03; 29 (3): 627-637.e5. ( PubMed, DOI )

  23. Masamu Inoue, Takehito Ono, Yoshitaka Kameo, Fumiyuki Sasaki, Takashi Ono, Taiji Adachi, Tomoki Nakashima. Forceful mastication activates osteocytes and builds a stout jawbone. Sci Rep. 2019.03; 9 (1): 4404. ( PubMed, DOI )

  24. Maia Inoue, Kazuo Okamoto, Asuka Terashima, Takeshi Nitta, Ryunosuke Muro, Takako Negishi-Koga, Toshio Kitamura, Tomoki Nakashima, Hiroshi Takayanagi. Arginine methylation controls the strength of γc-family cytokine signaling in T cell maintenance. Nat. Immunol.. 2018.11; 19 (11): 1265-1276. ( PubMed, DOI )

  25. Takehito Ono, Tomoki Nakashima. Recent advances in osteoclast biology. Histochem. Cell Biol.. 2018.04; 149 (4): 325-341. ( PubMed, DOI )

  26. Masayuki Tsukasaki, Noriko Komatsu, Kazuki Nagashima, Takeshi Nitta, Warunee Pluemsakunthai, Chisa Shukunami, Yoichiro Iwakura, Tomoki Nakashima, Kazuo Okamoto, Hiroshi Takayanagi. Host defense against oral microbiota by bone-damaging T cells. Nat Commun. 2018.02; 9 (1): 701. ( PubMed, DOI )

  27. Kazuo Okamoto, Tomoki Nakashima, Masahiro Shinohara, Takako Negishi-Koga, Noriko Komatsu, Asuka Terashima, Shinichiro Sawa, Takeshi Nitta, Hiroshi Takayanagi. Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. Physiol. Rev.. 2017.10; 97 (4): 1295-1349. ( PubMed, DOI )

  28. Kazuki Nagashima, Shinichiro Sawa, Takeshi Nitta, Alejandro Prados, Vasiliki Koliaraki, George Kollias, Tomoki Nakashima, Hiroshi Takayanagi. Targeted deletion of RANKL in M cell inducer cells by the Col6a1-Cre driver. Biochem. Biophys. Res. Commun.. 2017.09; ( PubMed, DOI )

  29. Y Fukushima-Nakayama, Takehito Ono, M Hayashi, M Inoue, H Wake, Takashi Ono, T Nakashima. Reduced Mastication Impairs Memory Function. J. Dent. Res.. 2017.08; 96 (9): 1058-1066. ( PubMed, DOI )

  30. Ayumi Shoji-Matsunaga, Takehito Ono, Mikihito Hayashi, Hiroshi Takayanagi, Keiji Moriyama, Tomoki Nakashima. Osteocyte regulation of orthodontic force-mediated tooth movement via RANKL expression. Sci Rep. 2017.08; 7 (1): 8753. ( PubMed, DOI )

  31. Kazuki Nagashima, Shinichiro Sawa, Takeshi Nitta, Masanori Tsutsumi, Tadashi Okamura, Josef M Penninger, Tomoki Nakashima, Hiroshi Takayanagi. Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. Nat. Immunol.. 2017.06; 18 (6): 675-682. ( PubMed, DOI )

  32. Lynett Danks, Noriko Komatsu, Matteo M Guerrini, Shinichiro Sawa, Marietta Armaka, George Kollias, Tomoki Nakashima, Hiroshi Takayanagi. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann. Rheum. Dis.. 2016.06; 75 (6): 1187-1195. ( PubMed, DOI )

  33. Asuka Terashima, Kazuo Okamoto, Tomoki Nakashima, Shizuo Akira, Koichi Ikuta, Hiroshi Takayanagi. Sepsis-Induced Osteoblast Ablation Causes Immunodeficiency. Immunity. 2016.06; 44 (6): 1434-1443. ( PubMed, DOI )

  34. Aritoshi Iida, Weirong Xing, Martine K F Docx, Tomoki Nakashima, Zheng Wang, Mamori Kimizuka, Wim Van Hul, Dietz Rating, Jürgen Spranger, Hirohumi Ohashi, Noriko Miyake, Naomichi Matsumoto, Subburaman Mohan, Gen Nishimura, Geert Mortier, Shiro Ikegawa. Identification of biallelic LRRK1 mutations in osteosclerotic metaphyseal dysplasia and evidence for locus heterogeneity. J. Med. Genet.. 2016.04; ( PubMed, DOI )

  35. Takehito Ono, Kazuo Okamoto, Tomoki Nakashima, Takeshi Nitta, Shohei Hori, Yoichiro Iwakura, Hiroshi Takayanagi. IL-17-producing γδ T cells enhance bone regeneration. Nat Commun. 2016.03; 7 10928. ( PubMed, DOI )

  36. Matteo M Guerrini, Kazuo Okamoto, Noriko Komatsu, Shinichiro Sawa, Lynett Danks, Josef M Penninger, Tomoki Nakashima, Hiroshi Takayanagi. Inhibition of the TNF Family Cytokine RANKL Prevents Autoimmune Inflammation in the Central Nervous System. Immunity. 2015.12; 43 (6): 1174-1185. ( PubMed, DOI )

  37. Hayashi M, Nakashima T, Takayanagi H. Semaphorins in bone homeostasis Semaphorin. 2015.02; 159-173. ( DOI )

  38. Haruhiko Nakamura, Tomoki Nakashima, Mikihito Hayashi, Naohiro Izawa, Tetsuro Yasui, Hiroyuki Aburatani, Sakae Tanaka, Hiroshi Takayanagi. Global epigenomic analysis indicates protocadherin-7 activates osteoclastogenesis by promoting cell-cell fusion. Biochem. Biophys. Res. Commun.. 2014.12; 455 (3-4): 305-311. ( PubMed, DOI )

  39. Noriko Komatsu, Kazuo Okamoto, Shinichiro Sawa, Tomoki Nakashima, Masatsugu Oh-hora, Tatsuhiko Kodama, Sakae Tanaka, Jeffrey A Bluestone, Hiroshi Takayanagi. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat. Med.. 2014.01; 20 (1): 62-68. ( PubMed, DOI )

  40. Hideaki Okura, Shintaro Sato, Sari Kishikawa, Satoshi Kaneto, Tomoki Nakashima, Nobuaki Yoshida, Hiroshi Takayanagi, Hiroshi Kiyono. Runx2-I isoform contributes to fetal bone formation even in the absence of specific N-terminal amino acids. PLoS ONE. 2014; 9 (9): e108294. ( PubMed, DOI )

  41. Charles A O'Brien, Tomoki Nakashima, Hiroshi Takayanagi. Osteocyte control of osteoclastogenesis. Bone. 2013.06; 54 (2): 258-263. ( PubMed, DOI )

  42. 中島友紀、林幹人. Semaphorin　 骨粗鬆症治療. 2013; 12 (1): 54-57.

  43. Tomoki Nakashima, Mikihito Hayashi, Hiroshi Takayanagi. New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol. Metab.. 2012.11; 23 (11): 582-590. ( PubMed, DOI )

  44. Tsuyoshi Miyazaki, Mitsuyasu Iwasawa, Tomoki Nakashima, Shuuichi Mori, Kazuhiro Shigemoto, Hiroaki Nakamura, Hideki Katagiri, Hiroshi Takayanagi, Sakae Tanaka. Intracellular and extracellular ATP coordinately regulate the inverse correlation between osteoclast survival and bone resorption. J. Biol. Chem.. 2012.11; 287 (45): 37808-37823. ( PubMed, DOI )

  45. Mikihito Hayashi, Tomoki Nakashima, Masahiko Taniguchi, Tatsuhiko Kodama, Atsushi Kumanogoh, Hiroshi Takayanagi. Osteoprotection by semaphorin 3A. Nature. 2012.05; 485 (7396): 69-74. ( PubMed, DOI )

  46. Nakashima T, Takayanagi H. RANK and RANKL. Encyclopedia of Signaling Molecules. 2012; 1581-1589.

  47. Tomoki Nakashima, Hiroshi Takayanagi. New regulation mechanisms of osteoclast differentiation. Ann. N. Y. Acad. Sci.. 2011.12; 1240 E13-E18. ( PubMed, DOI )

  48. Hideki Hayashi, Tomoko Kohno, Kiyoshi Yasui, Hiroyuki Murota, Tohru Kimura, Gordon S Duncan, Tomoki Nakashima, Kazuo Yamamoto, Ichiro Katayama, Yuhua Ma, Koon Jiew Chua, Takashi Suematsu, Isao Shimokawa, Shizuo Akira, Yoshinao Kubo, Tak Wah Mak, Toshifumi Matsuyama. Characterization of dsRNA-induced pancreatitis model reveals the regulatory role of IFN regulatory factor 2 (Irf2) in trypsinogen5 gene transcription. Proc. Natl. Acad. Sci. U.S.A.. 2011.11; 108 (46): 18766-18771. ( PubMed, DOI )

  49. Tomoki Nakashima, Mikihito Hayashi, Takanobu Fukunaga, Kosaku Kurata, Masatsugu Oh-Hora, Jian Q Feng, Lynda F Bonewald, Tatsuhiko Kodama, Anton Wutz, Erwin F Wagner, Josef M Penninger, Hiroshi Takayanagi. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med.. 2011.10; 17 (10): 1231-1234. ( PubMed, DOI )

  50. Erik Idrus, Tomoki Nakashima, Ling Wang, Mikihito Hayashi, Kazuo Okamoto, Tatsuhiko Kodama, Nobuyuki Tanaka, Tadatsugu Taniguchi, Hiroshi Takayanagi. The role of the BH3-only protein Noxa in bone homeostasis. Biochem. Biophys. Res. Commun.. 2011.07; 410 (3): 620-625. ( PubMed, DOI )

  51. Nakashima T, Takayanagi T. Osteoimmunology: the effect of inflammation on bone. Inflammation and Regeneration. 2011; 31 404-412.

  52. Keizo Nishikawa, Tomoki Nakashima, Shu Takeda, Masashi Isogai, Michito Hamada, Ayako Kimura, Tatsuhiko Kodama, Akira Yamaguchi, Michael J Owen, Satoru Takahashi, Hiroshi Takayanagi. Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation. J. Clin. Invest.. 2010.10; 120 (10): 3455-3465. ( PubMed, DOI )

  53. Mikihito Hayashi, Tomoki Nakashima, Tatsuhiko Kodama, Andrew P Makrigiannis, Noriko Toyama-Sorimachi, Hiroshi Takayanagi. Ly49Q, an ITIM-bearing NK receptor, positively regulates osteoclast differentiation. Biochem. Biophys. Res. Commun.. 2010.03; 393 (3): 432-438. ( PubMed, DOI )

  54. Keizo Nishikawa, Tomoki Nakashima, Mikihito Hayashi, Takanobu Fukunaga, Shigeaki Kato, Tatsuhiko Kodama, Satoru Takahashi, Kathryn Calame, Hiroshi Takayanagi. Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc. Natl. Acad. Sci. U.S.A.. 2010.02; 107 (7): 3117-3122. ( PubMed, DOI )

  55. Kou Kayamori, Kei Sakamoto, Tomoki Nakashima, Hiroshi Takayanagi, Kei-Ichi Morita, Ken Omura, Su Tien Nguyen, Yoshio Miki, Tadahiro Iimura, Akiko Himeno, Takumi Akashi, Hisafumi Yamada-Okabe, Etsuro Ogata, Akira Yamaguchi. Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells. Am. J. Pathol.. 2010.02; 176 (2): 968-980. ( PubMed, DOI )

  56. Tomoki Nakashima, Hiroshi Takayanagi. Osteoimmunology: crosstalk between the immune and bone systems. J. Clin. Immunol.. 2009.09; 29 (5): 555-567. ( PubMed, DOI )

  57. 中島友紀. RANKL/RANK/OPGと骨疾患　 THE BONE. 2009; 23 (4): 37-46.

  58. Tomoki Nakashima, Hiroshi Takayanagi. Osteoclasts and the immune system. J. Bone Miner. Metab.. 2009; 27 (5): 519-529. ( PubMed, DOI )

  59. Tomoki Nakashima, Hiroshi Takayanagi. The dynamic interplay between osteoclasts and the immune system. Arch. Biochem. Biophys.. 2008.05; 473 (2): 166-171. ( PubMed, DOI )

  60. J Andrew Pospisilik, Claude Knauf, Nicholas Joza, Paule Benit, Michael Orthofer, Patrice D Cani, Ingo Ebersberger, Tomoki Nakashima, Renu Sarao, Gregory Neely, Harald Esterbauer, Andrey Kozlov, C Ronald Kahn, Guido Kroemer, Pierre Rustin, Remy Burcelin, Josef M Penninger. Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell. 2007.11; 131 (3): 476-491. ( PubMed, DOI )

  61. Ayako Suematsu, Yasuhito Tajiri, Tomoki Nakashima, Junko Taka, Sae Ochi, Hiromi Oda, Kozo Nakamura, Sakae Tanaka, Hiroshi Takayanagi. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. Mod Rheumatol. 2007; 17 (1): 17-23. ( PubMed, DOI )

  62. Kojiro Sato, Ayako Suematsu, Tomoki Nakashima, Sayaka Takemoto-Kimura, Kazuhiro Aoki, Yasuyuki Morishita, Hiroshi Asahara, Keiichi Ohya, Akira Yamaguchi, Toshiyuki Takai, Tatsuhiko Kodama, Talal A Chatila, Haruhiko Bito, Hiroshi Takayanagi. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat. Med.. 2006.12; 12 (12): 1410-1416. ( PubMed, DOI )

  63. D Holstead Jones, Tomoki Nakashima, Otto H Sanchez, Ivona Kozieradzki, Svetlana V Komarova, Ildiko Sarosi, Sean Morony, Evelyn Rubin, Renu Sarao, Carlo V Hojilla, Vukoslav Komnenovic, Young-Yun Kong, Martin Schreiber, S Jeffrey Dixon, Stephen M Sims, Rama Khokha, Teiji Wada, Josef M Penninger. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006.03; 440 (7084): 692-696. ( PubMed, DOI )

  64. Teiji Wada, Tomoki Nakashima, Nishina Hiroshi, Josef M Penninger. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006.01; 12 (1): 17-25. ( PubMed, DOI )

  65. Teiji Wada, Tomoki Nakashima, Antonio J Oliveira-dos-Santos, Juerg Gasser, Hiromitsu Hara, Georg Schett, Josef M Penninger. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat. Med.. 2005.04; 11 (4): 394-399. ( PubMed, DOI )

  66. T Miyashita, A Kawakami, T Nakashima, S Yamasaki, M Tamai, F Tanaka, M Kamachi, H Ida, K Migita, T Origuchi, K Nakao, K Eguchi. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin. Exp. Immunol.. 2004.08; 137 (2): 430-436. ( PubMed, DOI )

  67. S Yamasaki, T Nakashima, A Kawakami, T Miyashita, F Tanaka, H Ida, K Migita, T Origuchi, K Eguchi. Cytokines regulate fibroblast-like synovial cell differentiation to adipocyte-like cells. Rheumatology (Oxford). 2004.04; 43 (4): 448-452. ( PubMed, DOI )

  68. Hiroaki Ida, Tomoki Nakashima, Nancy L Kedersha, Satoshi Yamasaki, Mingguo Huang, Yasumori Izumi, Taiichiro Miyashita, Tomoki Origuchi, Atsushi Kawakami, Kiyoshi Migita, Phillip I Bird, Paul Anderson, Katsumi Eguchi. Granzyme B leakage-induced cell death: a new type of activation-induced natural killer cell death. Eur. J. Immunol.. 2003.12; 33 (12): 3284-3292. ( PubMed, DOI )

  69. Tomoki Nakashima, Teiji Wada, Josef M Penninger. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol. 2003.05; 15 (3): 280-287. ( PubMed )

  70. Hiroyuki Murota, Youichiro Hamasaki, Tomoki Nakashima, Kazuo Yamamoto, Ichiro Katayama, Toshifumi Matsuyama. Disruption of tumor necrosis factor receptor p55 impairs collagen turnover in experimentally induced sclerodermic skin fibroblasts. Arthritis Rheum.. 2003.04; 48 (4): 1117-1125. ( PubMed, DOI )

  71. S Yamasaki, T Nakashima, A Kawakami, T Miyashita, H Ida, K Migita, K Nakata, K Eguchi. Functional changes in rheumatoid fibroblast-like synovial cells through activation of peroxisome proliferator-activated receptor gamma-mediated signalling pathway. Clin. Exp. Immunol.. 2002.08; 129 (2): 379-384. ( PubMed )

  72. Makoto Kamachi, Atsushi Kawakami, Satoshi Yamasaki, Ayumi Hida, Tomoki Nakashima, Hideki Nakamura, Hiroaki Ida, Masako Furuyama, Koto Nakashima, Kazutaka Shibatomi, Taiichiro Miyashita, Kiyoshi Migita, Katsumi Eguchi. Regulation of apoptotic cell death by cytokines in a human salivary gland cell line: distinct and synergistic mechanisms in apoptosis induced by tumor necrosis factor alpha and interferon gamma. J. Lab. Clin. Med.. 2002.01; 139 (1): 13-19. ( PubMed )

  73. S Hamasaki, T Nakamura, T Furuya, A Kawakami, K Ichinose, T Nakashima, Y Nishiura, S Shirabe, K Eguchi. Resistance of CD4-positive T lymphocytes to etoposide-induced apoptosis mediated by upregulation of Bcl-xL expression in patients with HTLV-I-associated myelopathy. J. Neuroimmunol.. 2001.07; 117 (1-2): 143-148. ( PubMed )

  74. S Yamasaki, A Kawakami, T Nakashima, H Nakamura, M Kamachi, S Honda, Y Hirai, A Hida, H Ida, K Migita, Y Kawabe, T Koji, I Furuichi, T Aoyagi, K Eguchi. Importance of NF-kappaB in rheumatoid synovial tissues: in situ NF-kappaB expression and in vitro study using cultured synovial cells. Ann. Rheum. Dis.. 2001.07; 60 (7): 678-684. ( PubMed )

  75. Y Hashimoto, N Matsuoka, A Kawakami, M Tsuboi, T Nakashima, K Eguchi, T Tomioka, T Kanematsu. Novel immunosuppressive effect of FK506 by augmentation of T cell apoptosis. Clin. Exp. Immunol.. 2001.07; 125 (1): 19-24. ( PubMed )

  76. S Urayama, A Kawakami, T Nakashima, S Yamasaki, A Hida, H Ida, M Kamachi, H Nakamura, T Origuchi, K Migita, Y Kawabe, K Eguchi. New disease-modifying antirheumatic drug 2 acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid (KE-298) selectively augments activation-induced T cell death. J. Lab. Clin. Med.. 2001.07; 138 (1): 11-17. ( PubMed, DOI )

  77. N Sera, A Kawakami, T Nakashima, H Nakamura, M Imaizumi, T Koji, Y Abe, T Usa, T Tominaga, E Ejima, K Ashizawa, N Yokoyama, N Ishikawa, K Ito, K Eguchi. Fas/FasL mediated apoptosis of thyrocytes in Graves' disease. Clin. Exp. Immunol.. 2001.05; 124 (2): 197-207. ( PubMed )

  78. K Shibatomi, H Ida, S Yamasaki, T Nakashima, T Origuchi, A Kawakami, K Migita, Y Kawabe, M Tsujihata, P Anderson, K Eguchi. A novel role for interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum.. 2001.04; 44 (4): 884-892. ( PubMed, DOI )

  79. T Origuchi, K Migita, T Nakashima, S Honda, S Yamasaki, A Hida, A Kawakami, T Aoyagi, Y Kawabe, K Eguchi. Regulation of cyclooxygenase-2 expression in human osteoblastic cells by N-acetylcysteine. J. Lab. Clin. Med.. 2000.11; 136 (5): 390-394. ( PubMed, DOI )

  80. Y Abe, A Kawakami, T Nakashima, E Ejima, K Fujiyama, T Kiriyama, A Ide, N Sera, T Usa, T Tominaga, K Ashizawa, N Yokoyama, K Eguchi. Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cells. J. Lab. Clin. Med.. 2000.11; 136 (5): 344-354. ( PubMed, DOI )

  81. Y Kobayashi, F Hashimoto, H Miyamoto, K Kanaoka, Y Miyazaki-Kawashita, T Nakashima, M Shibata, K Kobayashi, Y Kato, H Sakai. Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. J. Bone Miner. Res.. 2000.10; 15 (10): 1924-1934. ( PubMed, DOI )

  82. Y Ichinose, K Migita, T Nakashima, A Kawakami, T Aoyagi, K Eguchi. Effects of bisphosphonate on the release of MMP-2 from cultured human osteoblasts. Tohoku J. Exp. Med.. 2000.10; 192 (2): 111-118. ( PubMed )

  83. H Nakamura, A Kawakami, S Yamasaki, T Nakashima, M Kamachi, K Migita, Y Kawabe, T Nakamura, T Koji, Y Hayashi, K Eguchi. Expression and function of X chromosome-linked inhibitor of apoptosis protein in Sjögren's syndrome. Lab. Invest.. 2000.09; 80 (9): 1421-1427. ( PubMed )

  84. T Nakashima, Y Kobayashi, S Yamasaki, A Kawakami, K Eguchi, H Sasaki, H Sakai. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem. Biophys. Res. Commun.. 2000.09; 275 (3): 768-775. ( PubMed, DOI )

  85. S Urayama, A Kawakami, T Nakashima, M Tsuboi, S Yamasaki, A Hida, Y Ichinose, H Nakamura, E Ejima, T Aoyagi, T Nakamura, K Migita, Y Kawabe, K Eguchi. Effect of vitamin K2 on osteoblast apoptosis: vitamin K2 inhibits apoptotic cell death of human osteoblasts induced by Fas, proteasome inhibitor, etoposide, and staurosporine. J. Lab. Clin. Med.. 2000.09; 136 (3): 181-193. ( PubMed, DOI )

  86. K Kanaoka, Y Kobayashi, F Hashimoto, T Nakashima, M Shibata, K Kobayashi, Y Kato, H Sakai. A common downstream signaling activity of osteoclast survival factors that prevent nitric oxide-promoted osteoclast apoptosis. Endocrinology. 2000.08; 141 (8): 2995-3005. ( PubMed, DOI )

  87. A Hida, A Kawakami, T Nakashima, S Yamasaki, H Sakai, S Urayama, H Ida, H Nakamura, K Migita, Y Kawabe, K Eguchi. Nuclear factor-kappaB and caspases co-operatively regulate the activation and apoptosis of human macrophages. Immunology. 2000.04; 99 (4): 553-560. ( PubMed )

  88. A Kawakami, N Matsuoka, M Tsuboi, T Koji, S Urayama, N Sera, A Hida, T Usa, H Kimura, N Yokoyama, T Nakashima, N Ishikawa, K Ito, Y Kawabe, K Eguchi. CD4+ T cell-mediated cytotoxicity toward thyrocytes: the importance of Fas/Fas ligand interaction inducing apoptosis of thyrocytes and the inhibitory effect of thyroid-stimulating hormone. Lab. Invest.. 2000.04; 80 (4): 471-484. ( PubMed )

  89. T Origuchi, K Migita, T Nakashima, M Tominaga, H Nakamura, M Nakashima, T Aoyagi, A Kawakami, Y Kawabe, K Eguchi. IL-1-mediated expression of membrane type matrix-metalloproteinase in rheumatoid osteoblasts. Clin. Exp. Rheumatol.. 2000; 18 (3): 333-339. ( PubMed )

  90. A Kawakami, T Nakashima, H Sakai, S Urayama, S Yamasaki, A Hida, M Tsuboi, H Nakamura, H Ida, K Migita, Y Kawabe, K Eguchi. Inhibition of caspase cascade by HTLV-I tax through induction of NF-kappaB nuclear translocation. Blood. 1999.12; 94 (11): 3847-3854. ( PubMed )

  91. A Kawakami, T Nakashima, H Sakai, A Hida, S Urayama, S Yamasaki, H Nakamura, H Ida, Y Ichinose, T Aoyagi, I Furuichi, M Nakashima, K Migita, Y Kawabe, K Eguchi. Regulation of synovial cell apoptosis by proteasome inhibitor. Arthritis Rheum.. 1999.11; 42 (11): 2440-2448. ( PubMed, DOI )

  92. Y Shima, K Nakao, T Nakashima, A Kawakami, K Nakata, K Hamasaki, Y Kato, K Eguchi, N Ishii. Activation of caspase-8 in transforming growth factor-beta-induced apoptosis of human hepatoma cells. Hepatology. 1999.11; 30 (5): 1215-1222. ( PubMed, DOI )

  93. M Tsuboi, A Kawakami, T Nakashima, N Matsuoka, S Urayama, Y Kawabe, K Fujiyama, T Kiriyama, T Aoyagi, K Maeda, K Eguchi. Tumor necrosis factor-alpha and interleukin-1beta increase the Fas-mediated apoptosis of human osteoblasts. J. Lab. Clin. Med.. 1999.09; 134 (3): 222-231. ( PubMed )

  94. A Kawakami, M Tsuboi, S Urayama, N Matsuoka, S Yamasaki, A Hida, T Aoyagi, I Furuichi, T Nakashima, K Migita, Y Kawabe, M Nakashima, T Origuchi, K Eguchi. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J. Lab. Clin. Med.. 1999.06; 133 (6): 566-574. ( PubMed )

  95. A Kawakami, K Eguchi, N Matsuoka, M Tsuboi, T Koji, S Urayama, T Nakashima, Y Kawabe, S Nagataki. Expression and function of Fas and Fas ligand on peripheral blood lymphocytes in normal subjects. J. Lab. Clin. Med.. 1998.11; 132 (5): 404-413. ( PubMed )

  96. A Kawakami, N Matsuoka, M Tsuboi, S Urayama, T Nakashima, Y Kawabe, T Koji, T Aoyagi, K Maeda, K Eguchi. CD4+ T-cell-mediated cytotoxicity against staphylococcal enterotoxin B-pulsed synovial cells. Immunology. 1998.09; 95 (1): 38-46. ( PubMed )

  97. A Kawakami, T Nakashima, M Tsuboi, S Urayama, N Matsuoka, H Ida, Y Kawabe, H Sakai, K Migita, T Aoyagi, M Nakashima, K Maeda, K Eguchi. Insulin-like growth factor I stimulates proliferation and Fas-mediated apoptosis of human osteoblasts. Biochem. Biophys. Res. Commun.. 1998.06; 247 (1): 46-51. ( PubMed, DOI )

  98. T Nakashima, H Sasaki, M Tsuboi, A Kawakami, K Fujiyama, T Kiriyama, K Eguchi, M Ichikawa, S Nagataki. Inhibitory effect of glucocorticoid for osteoblast apoptosis induced by activated peripheral blood mononuclear cells. Endocrinology. 1998.04; 139 (4): 2032-2040. ( PubMed, DOI )

  99. T Kamiya, Y Kobayashi, K Kanaoka, T Nakashima, Y Kato, A Mizuno, H Sakai. Fluorescence microscopic demonstration of cathepsin K activity as the major lysosomal cysteine proteinase in osteoclasts. J. Biochem.. 1998.04; 123 (4): 752-759. ( PubMed )

  100. S Urayama, A Kawakami, N Matsuoka, M Tsuboi, T Nakashima, Y Kawabe, T Koji, K Eguchi. Fas/Fas ligand interaction regulates cytotoxicity of CD4+ T cells against staphylococcal enterotoxin B-pulsed endothelial cells. Biochem. Biophys. Res. Commun.. 1997.10; 239 (3): 782-788. ( PubMed, DOI )

  101. A Kawakami, K Eguchi, N Matsuoka, M Tsuboi, T Koji, S Urayama, K Fujiyama, T Kiriyama, T Nakashima, P K Nakane, S Nagataki. Fas and Fas ligand interaction is necessary for human osteoblast apoptosis. J. Bone Miner. Res.. 1997.10; 12 (10): 1637-1646. ( PubMed, DOI )

  102. 劉安豪、中島友紀. 歯周炎発病過程における歯根膜組織の役割と急性炎症進行期におけるIL-33/ST2経路の保護的な作用 実験医学. 2024.08; 42 (14): 2201-2204.

  103. 山下祐、斎藤充、中島友紀. 筋骨連関による運動器制御 アンチ・エイジング医学. 2024.04; 20 (2): 6-10.

  104. 小野岳人、中島友紀. 骨のメカノバイオロジー BIO Clinca. 2023.04; 38 (4): 21-25.

  105. 小野岳人、中島友紀. 骨粗鬆症における骨代謝回転 日本臨牀. 2023.01; 81 (1): 58-63.

  106. 小野岳人、中島友紀. 骨による心身の健康の維持 FOOD STYLE21. 2021.08; 25 (8): 34-37.

  107. 林幹人、中島友紀. 骨代謝調節機構 日本臨牀. 2020.12; 78 (12): 1990-1997.

  108. 中島友紀. スクレロスチンと力学的負荷 ファーマナビゲーター 抗スクレロスチン抗体編. 2020.08; 50-61.

  109. 中島友紀. スクレロスチンの遺伝子改変マウス ファーマナビゲーター 抗スクレロスチン抗体編. 2020.08; 82-89.

  110. 中島友紀. 骨恒常性をつかさどる骨リモデリングの制御機構 糖尿病・内分泌代謝科. 2020.07; 51 (1): 47-52.

  111. 中島友紀. 骨恒常性とその破綻を司るメカノバイオロジー 実験医学. 2020.04; 38 (7): 1120-1128.

  112. 中島友紀. 骨におけるメカノ・センシングとレスポンス 細胞. 2019.10; 51 (13): 654-658.

  113. 林幹人、中島友紀、高柳広. 骨細胞が産生するSema3Aはエストロゲンの作用を調整し骨老化を制御する 実験医学. 2019.05; 37 (9): 1464-1467.

  114. Mikihito Hayashi, Tomoki Nakashima. The bone and Wnt signaling : overview Clin Calcium. 2019.04; 29 (3): 277-282. ( PubMed, DOI )

  115. 中島友紀、小野岳人、林幹人. 運動器産生分子がつなぐ臓器連環と動的恒常性 実験医学（増刊）. 2019.04; 37 (7): 141-148.

  116. 中島友紀、松本俊夫. Wntシグナルが紡ぎ出す骨生物学とその医療応用 巻頭言 CLINICAL CALCIUM. 2019.03; 29 (3): 275-276.

  117. 中島友紀. 骨と筋肉の恒常性と全身性制御 実験医学（増刊号）. 2018.05; 36 (7): 1205-1211.

  118. Tomoki Nakashima. Molecular mechanism of bone metabolism and future therapeutic strategies. Clin Calcium. 2018.03; 28 (3): 344-352. ( PubMed, DOI )

  119. Takehito Ono, Tomoki Nakashima. Exercise and brain function Clin Calcium. 2018.01; 28 (1): 57-64. ( PubMed, DOI )

  120. 権藤理夢、中島友紀. 骨細胞：骨代謝の司令塔 分子リウマチ治療. 2017.11; 11 (1): 29-32.

  121. 中島友紀. 骨恒常性とメカノバイオロジー VIVA ORTHO. 2017.08; 90 8.

  122. 中島友紀. RANKL Biology-骨研究を越えて！ 腎と骨代謝. 2017.07; 30 (3): 165-166.

  123. 中島友紀. Myostatinによる破骨細胞分化と関節炎症への関与 リウマチ科. 2017.02; 57 (2): 195-198.

  124. Tomoki Nakashima. 骨代謝とメカノバイオロジー Clin Calcium. 2016.12; 26 (12): 1685-1695. ( PubMed, DOI )

  125. Mikihito Hayashi, Tomoki Nakashima. セマフォリンと骨粗鬆症 Clin Calcium. 2016.10; 26 (10): 1419-1427. ( PubMed, DOI )

  126. 林幹人、中島友紀. セマフォリンシグナルによる骨リモデリング制御 THE BONE. 2016.08; 30 (2): 151-156.

  127. Tomoki Nakashima. RANKL Biology ~Beyond the bone biology~ Clin Calcium. 2016.08; 26 (8): 1135-1142. ( PubMed, DOI )

  128. 中島友紀. 骨粗鬆症～骨の恒常性と破綻～ 医学のあゆみ. 2016.06; 257 (10): 985-991.

  129. 中島友紀. RANKL/OPGの産生細胞 ファーマナビゲーター 抗RANKL抗体編 . 2016.04; 60-69.

  130. 中島友紀. 骨細胞による破骨細胞分化の制御機構 骨・臓器ネットワークとオステサイト. 2016.02; 44-53.

  131. 中島友紀. 骨リモデリングと歯周組織の恒常性 Clin Calcium. 2015.08; 25 (8): 1220-1228. ( PubMed, DOI )

  132. 中島友紀. 骨研究の最前線〜骨を基軸とした多臓器連関システム FOOD STYLE21. 2015.06; 19 (6): 44-47.

  133. 中島友紀. RANKL/RANK/OPG 骨ぺディア. 2015.04; 124-125.

  134. 中島友紀. 骨破壊におけるRANK/RANKL 分子リウマチ治療. 2015.03; 8 (3): 44-48.

  135. 中島友紀. 破骨細胞研究と骨免疫学 日本臨床免疫学会会誌. 2015.01; 38 (1): 17-25.

  136. 中島友紀. 骨細胞の多彩な機能 Clin Calcium. 2015.01; 25 (6): 899-905. ( PubMed, DOI )

  137. 中島友紀. 骨細胞による骨リモデリングの制御 Clin Calcium. 2015.01; 25 (1): 21-28. ( PubMed, DOI )

  138. 中島友紀. 骨細胞による骨代謝調整 Bio Clinica. 2015; 30 (1): 28-32.

  139. 中島友紀. 骨転移とRANKL Clin Calcium. 2014.08; 24 (8): 1201-1208. ( PubMed, DOI )

  140. 中島友紀. 骨構成細胞のカップリングとコミュニケーション Clin Calcium. 2014.06; 24 (6): 853-861. ( PubMed, DOI )

  141. 林幹人、中島友紀. 造血系細胞から分化する破骨細胞分化制御 Clin Calcium. 2014.04; 24 (4): 487-500. ( PubMed, DOI )

  142. 中島友紀. 破骨細胞研究からみた骨破壊治療の新展開 リウマチ科. 2014; 52 (6): 655-662.

  143. 中島友紀. 乳癌の骨転移病変とRANKL 腎と骨代謝　. 2014; 27 15-23.

  144. 中島友紀. 骨細胞による骨制御 腎と骨代謝　. 2014; 27 (2): 136-146.

  145. 中島友紀. RANKLの多彩な作用 実験医学（増刊）. 2014; 32 (7): 43-52.

  146. 中島友紀. 骨細胞−骨代謝の司令塔 腎と骨代謝　. 2014; 27 (3): 191-197.

  147. 中島友紀. 骨細胞による骨リモデリングの制御 Current Therapy. 2014; 32 (10): 1015-1020.

  148. 中島友紀. 骨と筋肉との相互連関 Medical Practice. 2014; 31 (12): 1945-1948.

  149. 中島友紀. ストレスと骨の細胞間コミュニケーション Clin Calcium. 2013.11; 23 (11): 1595-1603. ( PubMed, DOI )

  150. 中島友紀. 骨構成細胞による骨恒常性の制御 Clin Calcium. 2013.02; 23 (2): 218-228. ( PubMed, DOI )

  151. 中島友紀. ビタミンDと骨免疫学 ビタミンDと疾患. 2013; 100-108.

  152. 林幹人、中島友紀、高柳広. セマフォリンによる骨代謝　 実験医学. 2013; 31 (4): 510-514.

  153. 林幹人、中島友紀、高柳広. セマフォリンによる骨代謝　 内科　. 2013; 111 (4): 711-715.

  154. 中島友紀、林幹人、高柳広. 骨リモデリングの制御機構 実験医学. 2013; 31 (6): 842-848.

  155. 中島友紀、高柳広：. 骨吸収作用 ファーマナビゲーターPTH編 . 2013; 46-54.

  156. 1中島友紀、林幹人、高柳広：. 骨細胞による骨吸収調節機構　 日本臨床 増刊号. 2013; 71 (4): 121-125.

  157. 中島友紀、林幹人、高柳広. 骨細胞による骨恒常性の制御 Medical Science Digest. 2013; 39 (8): 353-356.

  158. 中島友紀. 骨細胞による骨吸収制御 THE BONE. 2013; 27 (3): 49-57.

  159. 中島友紀. 乳癌細胞の進展のメカニズムとRANKL 癌と骨 . 2013; 87-94.

  160. 林幹人、中島友紀、高柳広. セマフォリンシグナルによる骨代謝調節 THE BONE. 2013; 24 (4): 379-383.

  161. 林幹人、中島友紀、高柳広. セマフォリンによる骨代謝 Clin Calcium. 2012.11; 22 (11): 1693-1699. ( PubMed, DOI )

  162. 骨細胞による骨吸収制御 Clin Calcium. 2012.05; 22 (5): 685-696. ( PubMed, DOI )

  163. 中島友紀、高柳広. 骨を作りか変える指令細胞の発見　 整形外科　. 2012; 63 (1): 50.

  164. 中島友紀. 骨細胞による骨恒常性の制御　 リウマチ科. 2012; 48 (3): 352-361.

  165. 林幹人、中島友紀、高柳広. Semaphorinシグナルによる骨代謝　 アンチ・エイジング医学. 2012; 8 (5): 704-709.

  166. 中島友紀、高柳広. 関節リウマチ骨破壊のメカニズム Jpn J Rehabil Med. 2012; 49 (10): 683-689.

  167. 中島友紀. 骨細胞による骨リモデリング制御 THE BONE. 2012; 26 (3): 5-10.

  168. 中島友紀、林幹人、高柳広. 骨細胞と骨リモデリング　 リウマチ科. 2012; 47 (5): 530-537.

  169. 中島友紀、林幹人、高柳広. 骨細胞による破骨細胞形成の制御機構　 内分泌・糖尿病・代謝内科. 2012; 34 (5): 457-464.

  170. 林幹人、中島友紀、高柳広. 骨リモデリングの制御機構　 細胞. 2012; 44 (7): 8-11.

  171. 中島友紀、高柳広. 破骨細胞分化における正と負の転写制御　 炎症と免疫. 2012; 20 (3): 227-233.

  172. 中島友紀、高柳広. 骨免疫学からみたRA治療の新展開　 最新医学. 2012; 62 (2): 203-211.

  173. 中島友紀、林幹人、高柳広. 骨疾患の治療標的としてのWnt シグナル リウマチ科. 2012; 48 (3): 363-368.

  174. 中島友紀、高柳広. 骨代謝における骨細胞の新たな役割　 Medical Practice. 2012; 29 (11): 1925-1928.

  175. 中島友紀、林幹人、高柳広. 破骨細胞の分化制御と骨免疫学 Clin Calcium. 2011.12; 21 (12): 93-102. ( PubMed, DOI )

  176. 中島友紀、高柳広. RANKLシグナルと骨免疫学 Clin Calcium. 2011.08; 21 (8): 1131-1140. ( PubMed, DOI )

  177. 中島友紀、高柳広. 骨免疫学から見た生物学的製剤療法と新展開　 骨粗鬆症治療. 2011; 10 (1): 53-59.

  178. 中島友紀、高柳広. 免疫系と破骨細胞 細胞工学. 2011; 30 (3): 250-258.

  179. 中島友紀、高柳広. 骨破壊制御の新たなアプローチ 医薬ジャーナル . 2009; 45 (10): 87-92.

  180. 林幹人、中島友紀、高柳広. 免疫と骨:骨免疫学Osteoimmunologyの幕開け 臨床検査. 2008; 52 (5): 556-560.

  181. 中島友紀、高柳広. 骨免疫学の最先端 Mebio . 2008; 25 (8): 24-35.

  182. 中島友紀、高柳広. 破骨細胞と免疫系 生体と科学 . 2007; 58 (3): 196-204.

  183. 中島友紀、高柳広. Osteoimmunology – 破骨細胞の誘導と炎症 整形外科 . 2007; 58 (12): 1615-1624.

  184. 中島友紀、Josef PENNINGER ：. がん細胞の遊走、骨転移を制御するRANKL 実験医学. 2006; 24 1777-1780.

  185. 和田悌司、中島友紀、仁科博史、Josef PENNINGER：. アダプター分子Gab2は骨密度を制御する 細胞工学. 2005; 24 704-705.

  186. 中島友紀. 破骨細胞分化因子 (RANKL) の可溶化のメカニズム THE BONE. 2001; 15 53-59.

  187. 中島友紀 . Receptor activator of NF-kB ligand (RANKL) の細胞膜からの遊離とcytokineによるその制御 日本骨代謝学会雑誌. 2001; 19 24-27.

  188. 中島友紀、川上純、江口勝美、北島勲. 骨形成系骨芽細胞のアポトーシス THE BONE. 1999; 13 65-72.

  189. 中島友紀. 骨細胞研究の最前線 THE BONE. 2019.05; 33 (1): 63-71.

< 前のページ - 次のページ >

  • 1
このページの先頭へ▲